文献速递乳腺乳腺X线

基于癌症干预与监测建模网络估计的乳腺癌筛查策略结局

Outcomes of Breast Cancer Screening Strategies Based on Cancer Intervention and Surveillance Modeling Network Estimates.
PubMed 文献 · Radiology · 2024-01-01

该研究比较了癌症干预与监测建模网络(CISNET)发布的四种乳腺癌筛查方案的模型估计值,评估40岁起每年筛查、40-74岁每两年筛查、50-74岁每两年筛查等方案的获益与风险。结果显示,40-79岁每年筛查的乳腺癌死亡率降低幅度最大(41.7%),避免死亡数最多(每1000人11.5例),获得生命年最多(每1000人230年),且每次检查的假阳性结果和良性活检率最低。

要点

  • 40-79岁每年筛查的乳腺癌死亡率降低为41.7%,高于50-74岁每两年筛查的25.4%和40-74岁每两年筛查的30%。
  • 40-79岁每年筛查避免乳腺癌死亡11.5/1000人,获得生命年230/1000人,均为各方案中最高。
  • 所有方案的每次检查假阳性率均低于10%(范围6.5%-9.6%),40-79岁每年筛查最低(6.5%)。

核心结论

  • CISNET 2023模型估计表明,从40岁开始每年进行乳腺癌筛查为女性提供最大获益,且每次检查的风险最低。

研究设计与样本

  • 基于美国假设队列的建模估计比较,评估四种筛查方案:50-74岁每两年筛查(2009和2016年USPSTF推荐)、40-74岁每两年筛查(2023年USPSTF草案推荐)、40-74岁每年筛查、40-79岁每年筛查。

诊断标准与关键数值

  • 40-79岁每年筛查的乳腺癌死亡率降低为41.7%,50-74岁每两年筛查为25.4%,40-74岁每两年筛查为30%。
  • 40-79岁每年筛查避免乳腺癌死亡11.5/1000人,获得生命年230/1000人;其他方案范围分别为6.7-11.5/1000人和121-230/1000人。
  • 所有方案每次检查假阳性结果低于10%(范围6.5%-9.6%),40-79岁每年筛查最低为6.5%。
  • 所有方案每次检查良性活检低于1.33%(范围0.88%-1.32%),40-79岁每年筛查最低为0.88%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background There is ongoing debate about recommendations for breast cancer screening strategies, specifically regarding the frequency of screening and the age at which to initiate screening. Purpose To compare estimates of breast cancer screening outcomes published by the Cancer Intervention and Surveillance Modeling Network (CISNET) to understand the benefits and risks of different screening scenarios. Materials and Methods Modeling estimates published by CISNET are based on hypothetical cohorts in the United States and compare women, starting at 40 years of age, who do and do not undergo breast cancer screening with mammography. The four scenarios assessed in this study, of multiple possible scenarios, were biennial screening ages 50-74 years (2009 and 2016 U.S. Preventive Services Task Force [USPSTF] recommendations), biennial screening ages 40-74 years (2023 USPSTF draft recommendation), annual screening ages 40-74 years, and annual screening ages 40-79 years. For each scenario, CISNET estimates of median lifetime benefits were compared. Risks that included false-positive screening results per examination and benign biopsies per examination were also calculated and compared. Results Estimates from CISNET 2023 showed that annual screening ages 40-79 years improved breast cancer mortality reduction compared with biennial screening ages 50-74 years and biennial screening ages 40-74 years (41.7%, 25.4%, and 30%, respectively). Annual screening ages 40-79 years averted the most breast cancer deaths (11.5 per 1000) and gained the most life-years (230 per 1000) compared with other screening scenarios (range, 6.7-11.5 per 1000 and 121-230 per 1000, respectively). False-positive screening results per examination were less than 10% for all screening scenarios (range, 6.5%-9.6%) and lowest for annual screening ages 40-79 years (6.5%). Benign biopsies per examination were less than 1.33% for all screening scenarios (range, 0.88%-1.32%) and lowest for annual screening ages 40-79 years (0.88%). Conclusion CISNET 2023 modeling estimates indicate that annual breast cancer screening starting at 40 years of age provides the greatest benefit to women and the least risk per examination. © RSNA, 2024 See also the editorial by Joe in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Monticciolo DL, Hendrick RE, Helvie MA, et al. Outcomes of Breast Cancer Screening Strategies Based on Cancer Intervention and Surveillance Modeling Network Estimates. Radiology. 2024. PMID: 38376405. doi:10.1148/radiol.232658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。